In vitro study to make sure the drug doesn’t change generic make up of a cell is one of the 2 key studies to complete IND approval for phase 2 with the FDA next year. Company doing its thing and ticking off major milestones before the first human dose in a couple of weeks time and before Walter Reed results. The company as stated many times is funded for the period ahead and have major non dilutive funding they are working on with the US defence force after Walter Reed results which based off mechanism of action look very strong
- Forums
- ASX - By Stock
- Ann: Brain Injury Program GLP Studies Further Update 6
NYR
nyrada inc.
Add to My Watchlist
11.5%
!
23.0¢

In vitro study to make sure the drug doesn’t change generic make...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
23.0¢ |
Change
-0.030(11.5%) |
Mkt cap ! $48.51M |
Open | High | Low | Value | Volume |
26.0¢ | 26.0¢ | 23.0¢ | $99.69K | 416.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 31363 | 22.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
23.5¢ | 68238 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 31363 | 0.225 |
4 | 74050 | 0.220 |
2 | 120005 | 0.215 |
1 | 100000 | 0.210 |
6 | 179378 | 0.200 |
Price($) | Vol. | No. |
---|---|---|
0.235 | 68238 | 2 |
0.240 | 141100 | 2 |
0.250 | 260000 | 2 |
0.260 | 129498 | 3 |
0.270 | 289139 | 3 |
Last trade - 12.47pm 19/06/2025 (20 minute delay) ? |
Featured News
NYR (ASX) Chart |
The Watchlist
RML
RESOLUTION MINERALS LTD
Craig Lindsay, In-Country CEO
Craig Lindsay
In-Country CEO
SPONSORED BY The Market Online